
Tamar Tadmor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4040770/publications.pdf Version: 2024-02-01



TAMAD TADMOD

#	Article	IF	CITATIONS
1	Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica, 2022, 107, 625-634.	3.5	83
2	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood, 2022, 139, 678-685.	1.4	96
3	Explainable machine learning for chronic lymphocytic leukemia treatment prediction using only inexpensive tests. Computers in Biology and Medicine, 2022, 145, 105490.	7.0	7
4	Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal of Cancer, 2022, 172, 65-75.	2.8	24
5	Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen. Hematological Oncology, 2021, 39, 129-133.	1.7	1
6	Daratumumab for relapsed AL amyloidosis—When cumulative realâ€world data precedes clinical trials: A multisite study and systematic literature review. European Journal of Haematology, 2021, 106, 184-195.	2.2	14
7	Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature Medicine, 2021, 27, 491-503.	30.7	118
8	Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy. Palliative Medicine, 2021, 35, 927-932.	3.1	8
9	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. Leukemia Research, 2021, 104, 106552.	0.8	4
10	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 2021, 35, 1864-1872.	7.2	28
11	The impact of COVID-19 on patients with hematological malignancies: the mixed-method analysis of an Israeli national survey. Supportive Care in Cancer, 2021, 29, 7591-7599.	2.2	14
12	Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Leukemia, 2021, 35, 2727-2730.	7.2	18
13	COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leukemia and Lymphoma, 2021, 62, 3384-3393.	1.3	25
14	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents. Cancers, 2021, 13, 5141.	3.7	16
15	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
16	Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study. Blood, 2021, 138, 3727-3727.	1.4	2
17	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. Blood, 2021, 138, 2641-2641.	1.4	0
18	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 2639-2639.	1.4	1

#	Article	IF	CITATIONS
19	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 72-72.	1.4	3
20	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	1.4	1
21	Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma. Blood, 2021, 138, 2748-2748.	1.4	8
22	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 2021, 138, 71-71.	1.4	36
23	Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e850-e857.	0.4	1
24	Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma. Leukemia Research, 2020, 99, 106476.	0.8	2
25	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. Hematological Oncology, 2020, 38, 439-445.	1.7	4
26	Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway. PLoS ONE, 2020, 15, e0230033.	2.5	2
27	Incidence and diagnosis of Richter transformation: transition from the era of chemoimmunotherapy to novel targeted agents. Leukemia and Lymphoma, 2020, 61, 1272-1274.	1.3	1
28	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. American Journal of Hematology, 2020, 95, 604-611.	4.1	12
29	The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2020, 11, 603569.	4.8	6
30	Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia. Blood, 2020, 136, 40-40.	1.4	29
31	First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study. Blood, 2020, 136, 27-28.	1.4	3
32	The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 17-17.	1.4	0
33	Clinical & Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice in Israel. Blood, 2020, 136, 23-24.	1.4	0
34	A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial. Blood, 2020, 136, 19-20.	1.4	0
35	Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors. Leukemia and Lymphoma, 2019, 60, 3449-3454.	1.3	4
36	A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. European Journal of Haematology, 2019, 103, 335-341.	2.2	5

#	Article	IF	CITATIONS
37	Ibrutinibâ€associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and nonâ€Hodgkin lymphoma: An observational study. Mycoses, 2019, 62, 1140-1147.	4.0	57
38	Primary peg-filgrastim prophylaxis versus filgrastim given "on demand―for neutropenia during therapy with cladribine for hairy cell leukemia. Leukemia Research, 2019, 82, 24-28.	0.8	2
39	Shiga-Like Toxin-Producing Escherichia coli Inducing Diarrhea in Patients with Multiple Myeloma Diagnosed by BioFire PCR-Film Array. Acta Haematologica, 2019, 142, 187-189.	1.4	2
40	Time to Understand More about Spontaneous Regression of Cancer. Acta Haematologica, 2019, 141, 156-157.	1.4	4
41	Five Ibrutinib-Associated Side Effects That All Clinicians Should Be Aware of. Acta Haematologica, 2019, 141, 254-255.	1.4	5
42	Lowâ€dose fludarabine and cyclophosphamide combined with standard dose rituximab (LDâ€FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. Hematological Oncology, 2019, 37, 185-192.	1.7	7
43	A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity. PLoS ONE, 2019, 14, e0209024.	2.5	6
44	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
45	Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints. Blood, 2019, 134, 982-982.	1.4	4
46	The Evaluation of Emotional Intelligence among Medical Students and Its Links with Non-cognitive Acceptance Measures to Medical School. Rambam Maimonides Medical Journal, 2019, 10, e0010.	1.0	11
47	Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study. Blood, 2019, 134, 3180-3180.	1.4	0
48	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. Blood, 2019, 134, 1766-1766.	1.4	0
49	COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting. Blood, 2019, 134, 1617-1617.	1.4	Ο
50	Fat Grafting after Implant Removal Due to Anaplastic Large Cell Lymphoma May Mimic Recurrence. Israel Medical Association Journal, 2019, 21, 520-522.	0.1	1
51	Absolute monocyte count at diagnosis could improve the prognostic role of early <scp>FDG</scp> â€ <scp>PET</scp> in classical Hodgkin lymphoma patients. British Journal of Haematology, 2018, 180, 600-602.	2.5	2
52	Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematological Oncology, 2018, 36, 349-354.	1.7	32
53	Persistently low lymphocyte counts after <scp>FCR</scp> therapy for chronic lymphocytic leukemia are associated with longer overall survival. Hematological Oncology, 2018, 36, 128-135.	1.7	6
54	Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?. Leukemia and Lymphoma, 2018, 59, 521-522.	1.3	3

#	Article	IF	CITATIONS
55	A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2018, 11, 57-70.	2.2	42
56	Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. Anticancer Research, 2018, 38, 6423-6429.	1.1	13
57	The Frequency and Prognostic Value of Neutrophilia in Chronic Lymphocytic Leukemia. Anticancer Research, 2018, 38, 4731-4734.	1.1	1
58	Cognitive impairment in hodgkin lymphoma survivors. British Journal of Haematology, 2018, 182, 670-678.	2.5	32
59	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia, 2018, 32, 1768-1777.	7.2	184
60	Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study. Blood, 2018, 132, 1972-1972.	1.4	1
61	Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience. Blood, 2018, 132, 3259-3259.	1.4	3
62	Hierarchical Involvement of Myeloid-Derived Suppressor Cells and Monocytes Expressing Latency-Associated Peptide in Plasma Cell Dyscrasias. Turkish Journal of Haematology, 2018, 35, 116-121.	0.5	2
63	Primary Marginal Zone Lymphoma of the Lung and Organizing Pneumonia: A Diagnostic Challenge. Israel Medical Association Journal, 2018, 20, 197-198.	0.1	1
64	Incidence and epidemiology of nonâ€Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of followâ€up. Hematological Oncology, 2017, 35, 599-607.	1.7	13
65	Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <scp>PET</scp> / <scp>CT</scp> is beneficial: a prospective multicentre trial of 355 patients. British Journal of Haematology, 2017, 178, 709-718.	2.5	31
66	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	1.4	193
67	The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 863-869.	0.4	11
68	Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment. Best Practice and Research in Clinical Haematology, 2017, 30, 92-98.	1.7	13
69	Neutrophil″ymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematological Oncology, 2017, 35, 561-566.	1.7	36
70	Time to Cure Hairy Cell Leukemia. Turkish Journal of Haematology, 2017, 34, 289-290.	0.5	2
71	Anaplastic Large T-Cell Lymphoma Associated with Breast Implants - Rare Disease. Israel Medical Association Journal, 2017, 19, 390-392.	0.1	0
72	Discordant bone marrow involvement in non-Hodgkin lymphoma. Blood, 2016, 127, 965-970.	1.4	28

#	Article	IF	CITATIONS
73	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. Blood, 2016, 128, 5699-5699.	1.4	1
74	Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?. Anticancer Research, 2016, 36, 2889-92.	1.1	5
75	Emotional intelligence: A unique group training in a hematology-oncology unit. Education for Health: Change in Learning and Practice, 2016, 29, 179-185.	0.3	1
76	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Haematologica, 2015, 100, 662-669.	3.5	19
77	Characteristics of primary splenic diffuse large <scp>B</scp> â€cell lymphoma and role of splenectomy in improving survival. Cancer, 2015, 121, 2909-2916.	4.1	34
78	Hairy cell leukemia: Uncommon clinical features, unusual sites of involvement and some rare associations. Best Practice and Research in Clinical Haematology, 2015, 28, 193-199.	1.7	12
79	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. Mayo Clinic Proceedings, 2015, 90, 756-764.	3.0	39
80	Epidemiology and environmental risk in hairy cell leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 175-179.	1.7	26
81	Treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a "successful couple,―but are they still relevant together?. Leukemia and Lymphoma, 2015, 56, 275-276.	1.3	0
82	Do lymphocytes count in myeloma? Are we absolutely sure?. Leukemia and Lymphoma, 2015, 56, 1193-1194.	1.3	2
83	Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e95-e99.	0.4	18
84	Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leukemia and Lymphoma, 2015, 56, 1949-1958.	1.3	48
85	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. Blood, 2015, 126, 3862-3862.	1.4	Ο
86	Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia. Anticancer Research, 2015, 35, 2861-6.	1.1	3
87	The growing link between multiple myeloma and myeloid derived suppressor cells. Leukemia and Lymphoma, 2014, 55, 2681-2682.	1.3	6
88	Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: to use, not to use, or give it as "FCR-LITE�. Leukemia and Lymphoma, 2014, 55, 733-734.	1.3	2
89	Defining the best cutâ€off value for lymphopenia in diffuse large B cell lymphoma treated with immunoâ€chemotherapy. British Journal of Haematology, 2014, 167, 133-136.	2.5	6
90	Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli <scp>CLL</scp> Study Group. European Journal of Haematology, 2014, 93, 29-33.	2.2	25

#	Article	IF	CITATIONS
91	Pegfilgrastim Prophylaxis for Cladribine-Induced Neutropenia in Patients with Hairy-Cell Leukemia. Acta Haematologica, 2014, 132, 118-121.	1.4	3
92	Richter's transformation to diffuse large Bâ€cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the <scp>I</scp> sraeli <scp>CLL</scp> <scp>S</scp> tudy <scp>G</scp> roup. American Journal of Hematology, 2014, 89, E218-22.	4.1	30
93	Response of cutaneous lesion of mantle cell lymphoma to lenalidomide. International Journal of Hematology, 2014, 100, 1-2.	1.6	3
94	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica, 2014, 99, 125-130.	3.5	77
95	Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Anticancer Research, 2014, 34, 785-90.	1.1	28
96	Absolute monocytosis at diagnosis correlates with survival in diffuse large Bâ€cell lymphoma—possible link with monocytic myeloidâ€derived suppressor cells. Hematological Oncology, 2013, 31, 65-71.	1.7	69
97	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leukemia Research, 2013, 37, 619-623.	0.8	24
98	Free light chain assay: doing a "good job―in Job's syndrome. Leukemia and Lymphoma, 2013, 54, 1131-113	2.1.3	0
99	Bone marrow fibrosis: a prognostic scar in hematological malignancies. Leukemia and Lymphoma, 2013, 54, 2349-2350.	1.3	0
100	Does monocyte count have prognostic significance in cancer?. Leukemia Research, 2013, 37, 1193-1194.	0.8	6
101	Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis. Cancer, 2013, 119, 1853-1859.	4.1	17
102	Elevated soluble CD 27 levels (TNF-receptor) may predict survival in diffuse large B-cell lymphoma - revisiting "the super- family " saga Leukemia and Lymphoma, 2012, 53, 1439-1440.	1.3	1
103	The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. Leukemia and Lymphoma, 2012, 53, 2339-2340.	1.3	13
104	Absolute monocyte count identifies high-risk patients with lymphomas: "absolutely―simple and "counts―mean a lot!. Leukemia and Lymphoma, 2012, 53, 519-520.	1.3	1
105	Rituximab in space: intrapleural and other novel routes of administration for lymphomas and lymphoid leukemias. Leukemia and Lymphoma, 2012, 53, 5-7.	1.3	2
106	Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices. Blood Reviews, 2012, 26, 15-23.	5.7	14
107	Increased incidence of chronic lymphocytic leukaemia and lymphomas in patients with <scp>M</scp> erkel cell carcinoma – a population based study of 335 cases with neuroendocrine skin tumour. British Journal of Haematology, 2012, 157, 457-462.	2.5	31
108	Sezary syndrome presenting with tumourous involvement of the breast detected by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography. British Journal of Haematology, 2012, 158, 432-432.	2.5	1

#	Article	IF	CITATIONS
109	Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment. Blood, 2012, 120, 1860-1860.	1.4	о
110	Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients Blood, 2012, 120, 2651-2651.	1.4	0
111	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas Blood, 2012, 120, 2647-2647.	1.4	О
112	Mantle cell lymphoma: curcumin nanodisks and possible new concepts on drug delivery for an incurable lymphoma. Leukemia and Lymphoma, 2011, 52, 1418-1420.	1.3	2
113	Microenvironment in peripheral T cell lymphomas: macrophages and angiogenesis as targets. Leukemia and Lymphoma, 2011, 52, 3-4.	1.3	Ο
114	Expanding the use of thrombopoietin mimetic drugs: what about chronic lymphocytic leukemia?. Leukemia and Lymphoma, 2011, 52, 558-559.	1.3	8
115	Alemtuzumab (Campath-1H) for chronic lymphocytic leukemia: a drug in search of its optimal schedule. Leukemia and Lymphoma, 2011, 52, 1831-1833.	1.3	1
116	Richter syndrome in chronic lymphocytic leukaemia manifesting only as tumorous hepatomegaly. British Journal of Haematology, 2011, 155, 135-135.	2.5	4
117	Myeloidâ€derived suppressor cells – their role in haematoâ€oncological malignancies and other cancers and possible implications for therapy. British Journal of Haematology, 2011, 153, 557-567.	2.5	49
118	The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunology, Immunotherapy, 2011, 60, 609-619.	4.2	122
119	Hypereosinophilia, JAK2V617F, and Buddâ€Chiari syndrome: Who is responsible for what?. American Journal of Hematology, 2011, 86, 223-224.	4.1	10
120	Hookah (narghile) smoking: A new emerging cause of secondary polycythemia. American Journal of Hematology, 2011, 86, 719-720.	4.1	15
121	Associations between multiple myeloma and other malignancies. Leukemia and Lymphoma, 2011, 52, 161-162.	1.3	4
122	FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes. Leukemia and Lymphoma, 2011, 52, 946-947.	1.3	1
123	â€~Hairy' cells: where are the roots of this leukemia?. Leukemia and Lymphoma, 2011, 52, 2205-2206.	1.3	Ο
124	Purine analog toxicity in patients with hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 38-42.	1.3	22
125	Two cases of agranulocytosis associated with cocaine use: is this phenomenon becoming more prevalent?. European Journal of Haematology, 2010, 84, 458-459.	2.2	5
126	An Unusual Case of Ankylosing Spondylitis Presenting with Severe Anemia. Acta Haematologica, 2010, 124, 176-178.	1.4	1

#	Article	IF	CITATIONS
127	Ocular adnexal mucosa-associated lymphoid tissue lymphomas: more clues but still a puzzle. Leukemia and Lymphoma, 2010, 51, 1951-1953.	1.3	3
128	Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leukemia and Lymphoma, 2010, 51, 1414-1423.	1.3	30
129	Posttransplant lymphoproliferative disorder after living donor liver transplant: are we improving incidence and outcome?. Leukemia and Lymphoma, 2010, 51, 1393-1394.	1.3	1
130	Individualizing cancer therapy. Leukemia and Lymphoma, 2010, 51, 1585-1587.	1.3	0
131	Lymphopenia a simple prognostic factor in lymphoma and other cancers: why not use it more as a guide?. Leukemia and Lymphoma, 2010, 51, 1773-1774.	1.3	10
132	A resurgence ofPneumocystisin aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?. Leukemia and Lymphoma, 2010, 51, 737-738.	1.3	18
133	Sorafenib – a small molecule with big promise?. Leukemia and Lymphoma, 2010, 51, 181-182.	1.3	3